Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.42 |
| ▸ | TUBB | P07437 | 3/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127072 | 0.94 | TUBB1 (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2903088 | 0.92 | TUBB1 (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2908544 | 0.90 | TUBB4A (0.39) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2903647 | 0.82 | MAOA (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4774294 | 0.80 | CA12 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2905355 | 0.79 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2453696 | 0.78 | CA2 (0.52) | SMN1; SMN2HSP90AA1KDM4EALDH1A1CA1 | |
| SCHEMBL2908764 | 0.76 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27545716 | 0.76 | TUBB4A (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2910499 | 0.74 | SIGMAR1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400510-B1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | KOWA CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| EP-1400513-B1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | KOWA CO (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-7135473-B2 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1400510-A1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| EP-1400513-A1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6632810-B2 | Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation | KOWA CO., LTD. (JP) | 2003-10-14 | — | — | US | disclosed |
| US-6552188-B2 | Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds | KOWA CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | TUBB4A 2439/4885TUBB 3443/4885TUBA3C 3941/4885 |
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | H1-0, DDAH1, AOC1 | TUBB4A 1405/4885TUBB 1773/4885TUBA3C 1158/4885 |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | TUBB4A 2439/4885TUBB 3443/4885TUBA3C 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.